150O_PRPertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG). (13th May 2019) - Huober, J; Ribi, K; Weder, P; Li, Q; Vanlemmens, L; Gerard, M-A; Lemonnier, J; Thürlimann, B; Boven, E; Bonnefoi, H